{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-003158","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2022-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.857857+00:00","generated_at":"2026-06-27T20:15:44.622610+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"PMV Pharma appoints Kirsten Flowers to Board; Dr. Peter Thompson resigns","bullets":["Dr. Peter Thompson resigned from the board and committees effective January 5, 2022; not related to any disagreement.","Kirsten Flowers appointed Class I director effective January 5, 2022, filling the vacancy until the 2024 annual meeting.","Ms. Flowers is Chief Commercial Officer of Kura Oncology, with prior roles at Array Biopharma and Pfizer.","Her compensation follows the Company's Outside Director Compensation Policy; an indemnification agreement was executed.","No arrangements or family relationships exist between Ms. Flowers and any other director or officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-003158","json":"https://secwatch.observer/filing/0001193125-22-003158.json","markdown":"https://secwatch.observer/filing/0001193125-22-003158.md","text":"https://secwatch.observer/filing/0001193125-22-003158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000119312522003158/0001193125-22-003158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000119312522003158/d86525d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:15:44.622610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0786a19a37","claim":"Peter Thompson resigned as Director at PMV Pharmaceuticals, Inc..","evidence_excerpt":"On January 5, 2022, Peter Thompson, M.D. notified PMV Pharmaceuticals, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors (the “Board”), which resignation was effected on January 5, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699382/000119312522003158/0001193125-22-003158-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"1f5eee7db1","claim":"Kirsten Flowers was appointed as Director at PMV Pharmaceuticals, Inc..","evidence_excerpt":"On January 5, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of the Company unanimously approved the appointment of Kirsten Flowers as a director and Class I director of the Company to fill the vacancy of Dr. Thompson’s seat on the Board of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699382/000119312522003158/0001193125-22-003158-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}